Pharmacare News Bulletins

Nova Scotia Pharmacare

Pharmacare News Bulletins

The Pharmacare News Bulletins, which are mailed to pharmacies and physicians, are listed below. They are an important source of information as they provide timely information on recent changes to the Pharmacare Programs.

Please continue to refer to the Pharmacare News Bulletins to stay current with Formulary and Pharmacare Program updates.

Latest Issues

May Bulletin Vol. 22 – 09
New Exception Status Benefits: Abrilada (adalimumab), Simlandi (adalimumab), Duobrii (halobetasol propionate and tazarotene); Criteria Update: Ofev (nintedanib); Public Funding of Pharmacist Assessment for COVID-19 Therapies; COVID-19 Immunizations

April Bulletin Vol. 22 – 08
New Exception Status Benefits: Zejula (niraparib), Adlyxine (lixisenatide), Entyvio (vedolizumab)

April Bulletin Vol. 22 – 07
Change to Maximum Reimbursable Prices

April Bulletin Vol. 22 – 06
Update on Audit of Patient Consent Documentation, Changes to Naloxone Kit Billing

March Bulletin Vol. 22 – 05
Virtual Care Update; Prescription Renewals for Pharmacy Closures; New Diabetic Products

February Bulletin Vol. 22 – 04
New Exception Status Benefits Ajovy (fremanezumab); Monoferric (ferric derisomaltose); Opsumit (macitentan); Riabni (rituximab). Criteria Updates Androgel and generic brands (testosterone); Testim (testosterone); Zofran and generic brands (ondansetron); Cosentyx (secukinumab)

February Bulletin Vol. 22 – 03
Change in Coverage of Biologics, Expansion of Community Pharmacist-led Anticoagulation Management Services (CPAMS), RN Prescribing

February Bulletin Vol. 22 – 02
New Exception Status Benefit: Nyvepria (pegfilgrastim)

January Bulletin Vol. 22 – 01
COVID-19 Updates to Public Coverage

Latest Issue

April Bulletin Vol. 22 – 03
New Exception Status Benefits: Zejula (niraparib), Adlyxine (lixisenatide), Entyvio (vedolizumab). Criteria Updates: Entyvio (vedolizumab), Lenvima (lenvatinib), Nexavar (sorafenib). New Benefits: Ceftazidime. New Diabetic Products

February Bulletin Vol. 22 – 02
New Exception Status Benefits Ajovy (fremanezumab); Monoferric (ferric derisomaltose); Opsumit (macitentan); Riabni (rituximab). Criteria Updates Androgel and generic brands (testosterone); Testim (testosterone); Zofran and generic brands (ondansetron); Cosentyx (secukinumab)

February Bulletin Vol. 22 – 01
New Exception Status Benefit Nyvepria (pegfilgrastim): Criteria Updates, Mozobil (plerixafor), Erleada (apalutamide), Xtandi (enzalutamide), Zytiga and generic brands (abiraterone), Riximyo (rituximab), Erelzi (etanercept)